A story on HispanicBusiness.com says pharmaceutical companies Merck and Pfizer, ordinarily rivals, are teaming up to develop a new medicine for type 2 diabetes.
Merck is paying $60 million up front for the rights to co-develop Pfizer’s diabetes drug called ertugliflozin, which is currently in late-stage development. Merck will also get the right to market ertugliflozin separately or in combination with its own diabetes treatment.
But recent health concerns have cropped up ...
continue reading...